- Home
- IRWD vs ODD Comparison
IRWD vs ODD Comparison
Compare IRWD & ODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IRWD | ODD |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 687.4M | 634.2M |
| IPO Year | 2009 | 2022 |
Fundamental Metrics
Financial Performance| Metric | IRWD | ODD |
|---|---|---|
| Price | $3.76 | $18.91 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 11 |
| Target Price | $6.10 | ★ $15.31 |
| AVG Volume (30 Days) | 1.5M | ★ 1.5M |
| Earning Date | 11-09-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1400.00 | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $298,276,000.00 | N/A |
| Revenue This Year | $59.19 | N/A |
| Revenue Next Year | $4.80 | $14.12 |
| P/E Ratio | ★ $7.49 | $16.73 |
| Revenue Growth | ★ 8.88 | N/A |
| 52 Week Low | $1.41 | $9.25 |
| 52 Week High | $5.78 | $60.86 |
Technical Indicators
Market Signals| Indicator | IRWD | ODD |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 60.64 |
| Support Level | $3.89 | $11.71 |
| Resistance Level | $3.96 | $19.87 |
| Average True Range (ATR) | 0.19 | 1.03 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 7.28 | 72.69 |
Price Performance
Historical ComparisonAbout IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
About ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage. Geographically, the company generates majority revenue from United states followed by other countries and Israel.